Showing results (461-470 of 634) with videos related to

Sort By:
Pageof 64
Cancer Research and Treatment|December 19, 2015
Growth Suppression and Induction of Chemosensitivity in Human Gallbladder Epithelial Carcinoma Cells (GBCE) by Adenovirus-Mediated Transfer of the Wild-type p53 GeneSung Bae Kim, Myung Hwan Kim, Sung Koo Lee, et al.
Japanese Journal of Clinical Oncology|March 7, 2009
Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytomaKyung-Sun Park, Jae-Lyun Lee, Hanjong Ahn, et al.
Toxicology and Applied Pharmacology|January 24, 2020
Amorphous silica nanoparticle-induced pulmonary inflammatory response depends on particle size and is sex-specific in ratsHyoung-Yun Han, Jae-Woo Cho, Eunsol Seong, et al.
Journal of Translational Medicine|October 27, 2021
The role of PDGFRA as a therapeutic target in young colorectal cancer patientsTae Won Kim, Hye Kyung Hong, Chung Lee, et al.
American Journal of Hematology|June 16, 2007
Chlamydia psittaci infection and clinicopathologic analysis of ocular adnexal lymphomas in KoreaChanghoon Yoo, Min-Hee Ryu, Jooryung Huh, et al.
Cancer Chemotherapy and Pharmacology|May 22, 2013
Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasisJun Ho Ji, Se Hoon Park, Jeeyun Lee, et al.
Anticancer Research|May 18, 2012
The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2Dok Hyun Yoon, Jae-Sik Shin, Dong-Hoon Jin, et al.
Cancer Research|October 22, 2017
[<sup>18</sup>F]fluorothymidine PET Informs the Synergistic Efficacy of Capecitabine and Trifluridine/Tipiracil in Colon CancerSeog-Young Kim, Jin Hwa Jung, Haeng Jung Lee, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2024
Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 studyAtsuo Takashima, Pilar García-Alfonso, Raimundo Manneh, et al.
Investigational New Drugs|December 29, 2010
A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapySang Joon Shin, Joong Bae Ahn, Kyung Soo Park, et al.
Pageof 64